Abstract:Background: Early stages of lung cancer have a better prognosis than later stages. The accuracy of current lung cancer early detection methods is relatively poor. We firstly try to use circRNAs of platelets enable blood-based early detection of lung cancer. Methods: We did a three-stage study that included healthy controls, benign lung nodule, and patients with diagnosed lung cancer from two hospitals in China. We used High-throughput Illumina sequencing analysis to profile circRNAs expression in the 8 patients with lung cancer and 8 non-cancer controls (including healthy controls and benign lung nodule patients). Using a training cohort of patients with lung cancer and non-cancer controls, we built a circRNAs classiﬁer to detect lung cancer. Then, the classiﬁers’ ability was validated in two independent cohorts of patients and non-cancer controls. We used the sensitivity, speciﬁcity, and area under the receiver operating characteristic curve (AUC) to evaluate diagnostic performance. Findings: Between Aug 1, 2018, and September 31, 2019, we recruited 88 participants to the training cohort, and 694 and 605 participants to the two independent validation cohorts. A signature comprising 23 circRNAs was identified by RNA-Seq analysis in the discovery stage. Then, four circRNAs (CD274, TIMP1, FLNA, ITGA2B) was found to have the possibility to serve as biomarkers for LC detection in the training stage by qRT-PCR. These selected four circRNAs from platelets was identified and subsequently assessed in the two independent validation cohorts. The area under the curve (AUC) for the five circRNAs from platelets (Pcs) were 0.975 in the validation cohort. In the following blinded test including the platelets from benign pulmonary nodule, LC patients and LC patients after surgery, Pcs correctly discriminated the patients with 90.6% sensitivity and 96.3% specificity. Interpretation: CircRNAs from platelets are very promising biomarkers for early stages of lung cancer diagnosis with very high sensitivity and specificity. This novel technology could serve as a Non-invasive, highly accurate diagnostic tool for lung nodule carriers that difficult to distinguish malignance from benign ones. Funding Statement: This work was supported by grants from National Natural Science Foundation of China (81572262), Jiangsu Province’s Key provincial Talents Program (ZDRCA2016028), 333 high class Talented Man Project (BRA2016516) and The Natural Science Foundation of the Jiangsu Higher Education Institution of China (18KJB320006). Declaration of Interests: None declared. Ethics Approval Statement: The study was approved by institutional ethics committee in each study center.

TEP linc-GTF2H2-1, RP3-466P17.2, and lnc-ST8SIA4-12 as novel biomarkers for lung cancer diagnosis and progression prediction

Development and Validation of Tumor-educated Blood Platelets Integrin Alpha 2b (ITGA2B) RNA for Diagnosis and Prognosis of Non-small-cell Lung Cancer through RNA-seq

Tumor-Educated Platelet RNA and Circulating Free RNA: Emerging Liquid Biopsy Markers for Different Tumor Types

LncRNAs and EGFRvIII sequestered in TEPs enable blood-based NSCLC diagnosis.

TEP SNORD12B, SNORA63, and SNORD14E as novel biomarkers for hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC)

Tumor-Educated Platelets as a Noninvasive Biomarker Source for Cancer Detection and Progression Monitoring.

TEP RNA: a new frontier for early diagnosis of NSCLC

PD-L1 mRNA derived from tumor-educated platelets as a potential immunotherapy biomarker in non-small cell lung cancer

Platelet RNA Enables Accurate Detection of Ovarian Cancer: an Intercontinental, Biomarker Identification Study.

RNA Sequencing Enables Systematic Identification of Platelet Transcriptomic Alterations in NSCLC Patients

RNA profiling of blood platelets noninvasively differentiates colorectal cancer from healthy donors and noncancerous intestinal diseases: a retrospective cohort study

The Analysis of Platelet-Derived circRNA Repertoire as Potential Diagnostic Biomarker for Non-Small Cell Lung Cancer

Plasma tRNA-derived small RNAs signature as a predictive and prognostic biomarker in lung adenocarcinoma

A Novel Neutrophil Extracellular Traps-Related Lncrna Signature Predicts Prognosis in Patients with Early-Stage Lung Adenocarcinoma

A Panel of Platelet Circrnas Serve As Biomarker for Lung Cancer Detection

Evaluation of tumor-educated platelet long non-coding RNAs (lncRNAs) as potential diagnostic biomarkers for colorectal cancer

Predicting Lung Adenocarcinoma Prognosis with a Novel Risk Scoring Based on Platelet-Related Gene Expression.

RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics

Comprehensive analysis to identify a novel PTEN-associated ceRNA regulatory network as a prognostic biomarker for lung adenocarcinoma

Identification of Biomarkers for the Detection of Early Stage Lung Adenocarcinoma by Microarray Profiling of Long Noncoding RNAs.

Identification of Stage-Specific Biomarkers in Lung Adenocarcinoma Based on Rna-Seq Data